Rare occurrence: Colitis induced by nab-paclitaxel in metastatic pancreatic cancer treatment - A case report

Abstract

Nab-Paclitaxel is a standard first-line treatment for metastatic pancreatic adenocarcinoma. While this therapy has shown promise, it can lead to rare but severe adverse effects, including colitis. We report a case of a 63-year-old patient with metastatic pancreatic adenocarcinoma treated with nab-paclitaxel who developed severe colitis after the first cycle. symptoms included abdominal pain, vomiting, diarrhoea, and melena. Laboratory, biopsy, and sigmoidoscopy reports were suggestive of drug-induced colitis. Treatment involved antibiotics, anti-inflammatory drugs, and supportive care.This case underscores the importance of monitoring patients for colitis during nab-paclitaxel-based chemotherapy and considering treatment modification if necessary. Early intervention is critical in managing this rare but potentially serious complication.